Vytrus Biotech S.A. (VYT) - Net Assets
Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has net assets worth €7.29 Million EUR (≈ $8.53 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.13 Million ≈ $13.01 Million USD) and total liabilities (€3.84 Million ≈ $4.49 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Vytrus Biotech S.A.'s assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.29 Million |
| % of Total Assets | 65.51% |
| Annual Growth Rate | 19.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.76 |
Vytrus Biotech S.A. - Net Assets Trend (2020–2024)
This chart illustrates how Vytrus Biotech S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Vytrus Biotech S.A. for the complete picture of this company's asset base.
Annual Net Assets for Vytrus Biotech S.A. (2020–2024)
The table below shows the annual net assets of Vytrus Biotech S.A. from 2020 to 2024. For live valuation and market cap data, see VYT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.29 Million ≈ $8.53 Million |
+37.80% |
| 2023-12-31 | €5.29 Million ≈ $6.19 Million |
+11.34% |
| 2022-12-31 | €4.75 Million ≈ $5.56 Million |
+11.83% |
| 2021-12-31 | €4.25 Million ≈ $4.97 Million |
+17.75% |
| 2020-12-31 | €3.61 Million ≈ $4.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vytrus Biotech S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 202.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.02 Million | 14.00% |
| Other Components | €6.27 Million | 86.00% |
| Total Equity | €7.29 Million | 100.00% |
Vytrus Biotech S.A. Competitors by Market Cap
The table below lists competitors of Vytrus Biotech S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tambun Indah Land Bhd
KLSE:5191
|
$88.79 Million |
|
Apex Biotechnology Corp
TW:1733
|
$88.80 Million |
|
Solesence, Inc. Common Stock
NASDAQ:SLSN
|
$88.88 Million |
|
Carnaby Resources Ltd
AU:CNB
|
$88.89 Million |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
$88.77 Million |
|
Handok
KO:002390
|
$88.74 Million |
|
Aniplus Inc
KQ:310200
|
$88.73 Million |
|
Canadian Life Companies Split Corp
TO:LFE
|
$88.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vytrus Biotech S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,292,253 to 7,292,825, a change of 2,000,572 (37.8%).
- Net income of 1,021,007 contributed positively to equity growth.
- Share repurchases of 137,956 reduced equity.
- New share issuances of 1,287,768 increased equity.
- Other factors decreased equity by 170,246.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.02 Million | +14.0% |
| Share Repurchases | €137.96K | -1.89% |
| Share Issuances | €1.29 Million | +17.66% |
| Other Changes | €-170.25K | -2.33% |
| Total Change | €- | 37.80% |
Book Value vs Market Value Analysis
This analysis compares Vytrus Biotech S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 20.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 38.63x to 20.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €0.51 | €19.60 | x |
| 2021-12-31 | €0.61 | €19.60 | x |
| 2022-12-31 | €0.69 | €19.60 | x |
| 2023-12-31 | €0.79 | €19.60 | x |
| 2024-12-31 | €0.97 | €19.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vytrus Biotech S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.00%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.24%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.53x
- Recent ROE (14.00%) is above the historical average (10.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 6.01% | 12.72% | 0.27x | 1.72x | €-144.08K |
| 2021 | 10.59% | 16.05% | 0.39x | 1.69x | €24.98K |
| 2022 | 12.73% | 16.44% | 0.46x | 1.68x | €129.92K |
| 2023 | 10.30% | 14.58% | 0.40x | 1.76x | €15.72K |
| 2024 | 14.00% | 20.24% | 0.45x | 1.53x | €291.72K |
Industry Comparison
This section compares Vytrus Biotech S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $17,257,303
- Average return on equity (ROE) among peers: -90.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vytrus Biotech S.A. (VYT) | €7.29 Million | 6.01% | 0.53x | $88.79 Million |
| Atrys Health SL (ATRY) | $23.30 Million | 1.25% | 0.73x | $214.84 Million |
| Biotechnology Assets S.A. (BST) | $3.84 Million | -223.94% | 4.26x | $13.52 Million |
| Oryzon Genomics SA (ORY) | $34.43 Million | -15.09% | 0.77x | $227.73 Million |
| Pharma Mar S.A. (PHM) | $7.46 Million | -123.12% | 15.73x | $1.56 Billion |
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more